Large-scale pharmaceutical and non-pharmaceutical interventions in a natural pandemic of an acute, self-limiting viral infection drive the dominant propagation of more infectious immune escape variants. This complicates and delays Nature’s control over the pandemic. Once the train of immune escape gains momentum, highly Covid-19 (C-19) vaccinated populations will inevitably reach the terminus of high virulence, referred to as 'HIVICRON'. Consequently, the toll exacted by this interference on the population by Nature will be MUCH higher compared to if human intervention had been limited to appropriately treating vulnerable individuals at an early stage of symptomatic infection. The losses incurred by large-scale pharmaceutical and non-pharmaceutical interventions are attributable to the immune evasion they induce. This indirectly leads to the derailment of the immune response, while simultaneously causing a surge in breakthrough infections that further extend the immune evasion to more conserved domains within the spike protein and other viral proteins in general. This causes highly C-19 vaccinated populations to initially exert high immune pressure on the infectiousness of the virus, and ultimately on its overall transmission potential. This progression inevitably culminates in a final stage where the immune pressure on the virus's capacity to propagate and survive rises to an extent that it is compelled to spread massively within the host rather than from one host to another. I have no doubt that this evolution will result in a rapid dissemination of the virus from the upper respiratory tract to all organs, leading to swift and extensive mortality in these populations.
In conclusion, only after causing some painful detours and acquiring a high level of virulence in highly C-19 vaccinated populations, will population immunity eventually end the pandemic of immune escape and drive the virus into endemicity (as illustrated in fig. A appended below). This sharply contrasts with how a natural SARS-CoV-2 pandemic would have transitioned into endemicity (as illustrated in fig. B below).
I strongly recommend C-19 vaccinees to ensure access to drugs with proven antiviral activity that are safe, broadly available at an affordable cost, and to use them prophylactically as soon as a wave of high viral virulence emerges in any highly C-19 vaccinated population.
Geert Vanden Bossche received his DVM from the University of Ghent, Belgium, and his PhD degree in Virology from the University of Hohenheim, Germany. He held adjunct faculty appointments at universities in Belgium and Germany. After his career in Academia, Geert joined several vaccine companies (GSK Biologicals, Novartis Vaccines, Solvay Biologicals) to serve various roles in vaccine R&D as well as in late vaccine development.
Geert then moved on to join the Bill & Melinda Gates Foundation’s Global Health Discovery team in Seattle (USA) as Senior Program Officer; he then worked with the Global Alliance for Vaccines and Immunization (GAVI) in Geneva as Senior Ebola Program Manager. At GAVI he tracked efforts to develop an Ebola vaccine. He also represented GAVI in fora with other partners, including WHO, to review progress on the fight against Ebola and to build plans for global pandemic preparedness.
Back in 2015, Geert scrutinized and questioned the safety of the Ebola vaccine that was used in ring vaccination trials conducted by WHO in Guinea. His critical scientific analysis and report on the data published by WHO in the Lancet in 2015 was sent to all international health and regulatory authorities involved in the Ebola vaccination program. After working for GAVI, Geert joined the German Center for Infection Research in Cologne as Head of the Vaccine Development Office. He is at present primarily serving as a Biotech / Vaccine consultant while also conducting his own research on Natural Killer cell-based vaccines.
Email: info@voiceforscienceandsolidarity.org
.svg){kind=small}
